Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Archives of Ophthalmology
doi 10.1001/archopht.125.10.1357
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Single-Session Photodynamic Therapy Combined With Intravitreal Bevacizumab and Triamcinolone for Neovascular Age-Related Macular Degeneration

BMC Ophthalmology
MedicineOphthalmology
2007English

Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Cohort Study for the UK.

Health Technology Assessment
MedicineHealth Policy
2012English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Photodynamic Therapy for Age-Related Macular Degeneration

The Review of Laser Engineering
2005English

Focal Macular Electroretinograms After Intravitreal Injections of Bevacizumab for Age-Related Macular Degeneration

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2012English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Combination of Bevacizumab and Photodynamic Therapy vs. Bevacizumab Monotherapy for the Treatment of Wet Age‑related Macular Degeneration: A Meta‑analysis of Randomized Controlled Trials

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

Effect of ARMS2 Gene Polymorphism on Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

Genetics and Molecular Research
MedicineGeneticsMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy